James has twenty-five years of operations management experience spanning a range of technical industries and applications from nuclear-powered propulsion systems and industrial chemical processing to biological research laboratories. Additionally, James has fifteen years of protein engineering and bioprocessing experience focused on recombinant antibodies for drug screening and development.
James joined Sevion Therapeutics as Chief Technology Officer in 2014 upon the merger of Fabrus and Senesco, where he was responsible for managing the corporate and research operations for a publicly-traded company as well as mammalian cell line development and recombinant protein production. Prior to his time a Sevion, he managed corporate and research operations for Fabrus starting in 2007 as the Chief Operating Officer and co-founder.
James received his Ph.D. from The Scripps Research Institute working jointly with the Genomics Institute of the Novartis Research Foundation and was a staff scientist at Kythera Biopharmaceuticals, Inc. Prior to receiving his doctorate, James was a qualified and decorated nuclear propulsion plant mechanic and work center supervisor in the U.S. Navy on board both USS Enterprise and USS Texas.
